Bronchial Spasms, also known as Bronchospasm, is a sudden contraction of muscles in the walls of the bronchioles. It is caused by the release (degranulation) of substances from mast cells or basophils under the influence of anaphylatoxins. It causes difficulty in breathing which ranges from mild to severe.


Bronchial Spasm Market Dynamics
Bronchial Spasm Market growth is driven by the increase in incidence and prevalence of asthma and COPD, technological advancements, and growing chronic lung disease (including emphysema and chronic bronchitis), anaphylactic shock, or an allergic reaction to chemicals.

Increasing technological advancements are expected to drive growth in the forecast period.

The advanced technological requirement in healthcare products is one of the drivers of this market. Currently, technology is getting way more advanced than traditional techniques. In pulmonary diseases, many people are still unaware of its symptoms. However, according to the World Health Organization (WHO), the current affected people of asthma are around 235 million worldwide. Due to a lack of awareness about asthma and COPD, leading to the increasing number of incidences of these diseases and driving the demand for smart inhalers. Smart inhalers can be connected to multiple devices to take the patients' health updates daily, especially for respiratory conditions like asthma and COPD. It has sensors that remind about the daily dosage and how much it can take. As technology is getting smarter, it's getting useful in healthcare products. However, for people using different medications to control bronchospasms, it also provides multi-meditational permissions. Smart inhalers are one of the examples of smart technology. Now, it is helpful for patients suffering from Bronchospasm to poise their dosage. Generally, Bronchospasm usually starts with inhaled medications known as short-acting beta2-agonists.

In addition, the rising adoption of IoT devices in healthcare is also expected to supplement the market growth. Population and pollution are two main factors which are rapidly growing. With the increasing population, several diseases are coming to know. Some can be diagnosed within a few days, and some can be analyzed for a limited period. For instance, Bronchospasm is a chronic disease, and it is not for a limited period. It affects people for life long. This disease blocks the lines from which the air flows in the body.

Major side effects associated with bronchodilators are likely to hamper market growth.

On the contrary, side effects of bronchodilators trembling, particularly in the hands, nervous tension, headaches, suddenly noticeable heartbeats (palpitations), muscle cramps, a dry mouth, constipation and cough are likely to hamper the market growth.

Bronchial Spasm Market- Industry Analysis
COVID-19 Impact Analysis

According to a research study by José Luis Izquierdo et al., published in European Respiratory Journal, March 2021, the study results found that allergy-related factors such as rhinitis and eczema were less common in asthmatic patients with COVID-19. There is a high prevalence of these comorbidities observed in patients with COVID-19 who required hospital admission. Furthermore, the use of inhaled corticosteroids (ICS) was lower in patients who required hospitalization due to COVID-19 than non-hospitalized patients (48.3% versus 61.5%). Although patients treated with biologics showed increased severity and more comorbidities at the ear, nose, and throat level, COVID-19-related hospitalizations in these patients were relatively low (0.23%). Thus, patients with asthma and COVID-19 were older and at increased risk due to comorbidity-related factors. Inhaled corticosteroids (ICS) and biologics are generally safe and may be associated with a protective effect against severe COVID-19 infection.

Bronchial Spasm Market Segment Analysis
The short-acting beta2-agonists segment is expected to hold the largest share in this market segment.

Short-acting beta2-agonists (SABA) are a type of bronchodilator. These are the most common immediate-relief drugs for treating asthma attacks and managing acute and stable exacerbations of chronic obstructive pulmonary disease (COPD). Treatment of Bronchospasm usually starts with inhaled medications known as short-acting beta2-agonists. Ventolin or Proventil (albuterol) are common medications used for difficulty breathing or shortness of breath. Albuterol helps to open up the airways. Salbutamol is the most commonly prescribed short-acting beta2-agonists (SABA) and is available under different brand names such as Salamol, Ventolin, and Proventil. The usage of short-acting beta-2-agonists SABAs regularly for at least seven days in stable COPD is associated with the decrease in breathlessness and improvement in post-bronchodilator lung function within 5 minutes. The inhaled form of the drug is available in metered-dose inhalers and as a liquid for compressor-driven nebulizers. Short-acting beta2-agonists (SABA) are utilized to treat symptoms in intermittent asthma, prevent asthma symptoms before exercise, and provide quick relief of symptoms during asthma attacks. A combination of ipratropium and short-acting beta2-agonists (SABA) in severe, acute asthma episodes improves lung function and fewer hospital visits.

Bronchial Spasm Market Geographical Analysis
North America region holds the largest market share of the global bronchial spasm market.

North America region is expected to dominate the bronchial spasm market during the forecast period. This growth can be attributed to the rising incidence of diseases such as COPD and asthma, the aging population, increasing research and development activities, and the presence of key market players.

In the United States, asthma is more common in adult women than adult men. According to the Centers for Disease Control and Prevention 2020 report, in the United States, approximately 25 million Americans have asthma. This equals about 1 in 13 Americans, including 8 percent of adults and 7 percent of children. About 20 million U.S. adults age 18 and over have asthma. Similarly, asthma is a significant public health concern in Canada. As a lifelong respiratory illness, asthma affects the work productivity, quality of life, mental health, and psychological wellbeing of the Canadian population. In Canada, over 3.8 million individuals had asthma in 2019, as per asthma Canada's 2019 annual asthma survey report. The high number of patients affected by asthma increases the demand for drugs to treat target disease, thereby boosting the growth of this region.

Moreover, the rise in the number of initiatives undertaken by government and non-government organizations is increasing the overall revenue. For instance, CDC's National Asthma Control Program (NACP) provides funds for educating asthma-affected patients. Such initiatives are likely to raise awareness about asthma, which will increase the adoption of drugs in the treatment of asthma, leading to verticle growth.

Bronchial Spasm Market Competitive Landscape
The global bronchial spasm market is highly competitive with the presence of local and international companies. Some of the key players contributing to the market's growth include GlaxoSmithKline Plc, Merck Sharp & Dohme Corp, AstraZeneca plc, Boehringer Ingelheim International GmbH, Novartis AG, Teva Pharmaceuticals USA, Inc, Viatris Inc and Sunovion Pharmaceuticals Inc.

Key Companies to Watch
Novartis AG

Overview: Novartis AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland, established in 1996. The company has over 105,794 employees and operates business through innovative medicine and Sandoz. Made up of two business units– Novartis Pharmaceuticals, which includes Novartis Gene Therapies, and Novartis Oncology – our Innovative Medicines Division commercializes innovative patented medicines to enhance health outcomes for patients and healthcare professionals. Sandoz is a global leader in generic pharmaceuticals and biosimilars that pioneers novel approaches to help people worldwide access high-quality medicines.

Product Portfolio: Seebri Breezhaler (Glycopyrronium)- Seebri capsules for inhalation contain the active ingredient glycopyrronium bromide (glycopyrrolate) in a capsule form. The pills are for oral inhalation only. The powder from the capsule is inhaled (breathed into the lungs) using the Breezhaler inhalation device provided with the medicine.